ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF

ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF

The present invention relates to an antibody that specifically binds to folate receptor alpha (FOLR1) and thereby blocks the activity of FOLR1, and relates to a modified antibody that significantly enhances binding ability to an antigen by enhancing the binding ability of a conventional antibody. Th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHUNG HYE-SHIN, LEE SUN-BAE, PARK SOON-JAE
Format: Patent
Sprache:chi ; eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator CHUNG HYE-SHIN
LEE SUN-BAE
PARK SOON-JAE
description The present invention relates to an antibody that specifically binds to folate receptor alpha (FOLR1) and thereby blocks the activity of FOLR1, and relates to a modified antibody that significantly enhances binding ability to an antigen by enhancing the binding ability of a conventional antibody. The modified antibody according to the present invention provided sequences in which the antigen binding site originally possessed by a parent antibody was replaced with amino acids that bind better with an antigen while retaining the basic structure of the parent antibody, thereby enhancing the binding ability with the antigen. In addition, the antibody or an antigen-binding fragment thereof according to the present invention can be used for the prophylactic or therapeutic use of cancer, and canbe used for diagnosis of diseases. The modified antibody according to the present invention provides an amino acid-substituted sequence which better binds an antigen binding site originally possessedby a parent antibody to an
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN112424227A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN112424227A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN112424227A3</originalsourceid><addsrcrecordid>eNrjZDB39AvxdPJ3iVQIDnB19nTzdHb08YlUcPL0c_H0c1cI8Vdw8_cJMlRw9HNRCA12DVYI8XANcvV342FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8c5-hoZGJkBoZO5oTIwaACKUJ-Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF</title><source>esp@cenet</source><creator>CHUNG HYE-SHIN ; LEE SUN-BAE ; PARK SOON-JAE</creator><creatorcontrib>CHUNG HYE-SHIN ; LEE SUN-BAE ; PARK SOON-JAE</creatorcontrib><description>The present invention relates to an antibody that specifically binds to folate receptor alpha (FOLR1) and thereby blocks the activity of FOLR1, and relates to a modified antibody that significantly enhances binding ability to an antigen by enhancing the binding ability of a conventional antibody. The modified antibody according to the present invention provided sequences in which the antigen binding site originally possessed by a parent antibody was replaced with amino acids that bind better with an antigen while retaining the basic structure of the parent antibody, thereby enhancing the binding ability with the antigen. In addition, the antibody or an antigen-binding fragment thereof according to the present invention can be used for the prophylactic or therapeutic use of cancer, and canbe used for diagnosis of diseases. The modified antibody according to the present invention provides an amino acid-substituted sequence which better binds an antigen binding site originally possessedby a parent antibody to an</description><language>chi ; eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210226&amp;DB=EPODOC&amp;CC=CN&amp;NR=112424227A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210226&amp;DB=EPODOC&amp;CC=CN&amp;NR=112424227A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHUNG HYE-SHIN</creatorcontrib><creatorcontrib>LEE SUN-BAE</creatorcontrib><creatorcontrib>PARK SOON-JAE</creatorcontrib><title>ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF</title><description>The present invention relates to an antibody that specifically binds to folate receptor alpha (FOLR1) and thereby blocks the activity of FOLR1, and relates to a modified antibody that significantly enhances binding ability to an antigen by enhancing the binding ability of a conventional antibody. The modified antibody according to the present invention provided sequences in which the antigen binding site originally possessed by a parent antibody was replaced with amino acids that bind better with an antigen while retaining the basic structure of the parent antibody, thereby enhancing the binding ability with the antigen. In addition, the antibody or an antigen-binding fragment thereof according to the present invention can be used for the prophylactic or therapeutic use of cancer, and canbe used for diagnosis of diseases. The modified antibody according to the present invention provides an amino acid-substituted sequence which better binds an antigen binding site originally possessedby a parent antibody to an</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB39AvxdPJ3iVQIDnB19nTzdHb08YlUcPL0c_H0c1cI8Vdw8_cJMlRw9HNRCA12DVYI8XANcvV342FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8c5-hoZGJkBoZO5oTIwaACKUJ-Q</recordid><startdate>20210226</startdate><enddate>20210226</enddate><creator>CHUNG HYE-SHIN</creator><creator>LEE SUN-BAE</creator><creator>PARK SOON-JAE</creator><scope>EVB</scope></search><sort><creationdate>20210226</creationdate><title>ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF</title><author>CHUNG HYE-SHIN ; LEE SUN-BAE ; PARK SOON-JAE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN112424227A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>CHUNG HYE-SHIN</creatorcontrib><creatorcontrib>LEE SUN-BAE</creatorcontrib><creatorcontrib>PARK SOON-JAE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHUNG HYE-SHIN</au><au>LEE SUN-BAE</au><au>PARK SOON-JAE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF</title><date>2021-02-26</date><risdate>2021</risdate><abstract>The present invention relates to an antibody that specifically binds to folate receptor alpha (FOLR1) and thereby blocks the activity of FOLR1, and relates to a modified antibody that significantly enhances binding ability to an antigen by enhancing the binding ability of a conventional antibody. The modified antibody according to the present invention provided sequences in which the antigen binding site originally possessed by a parent antibody was replaced with amino acids that bind better with an antigen while retaining the basic structure of the parent antibody, thereby enhancing the binding ability with the antigen. In addition, the antibody or an antigen-binding fragment thereof according to the present invention can be used for the prophylactic or therapeutic use of cancer, and canbe used for diagnosis of diseases. The modified antibody according to the present invention provides an amino acid-substituted sequence which better binds an antigen binding site originally possessedby a parent antibody to an</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN112424227A
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title ANTIBODY SPECIFICALLY BINDING TO FOLR1 AND USES THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A00%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHUNG%20HYE-SHIN&rft.date=2021-02-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN112424227A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true